• Mashup Score: 5

    This interactive tool demonstrates data from the Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021, which reports the magnitude of total CVD burden, including by disease state and risk factors across 21 global regions. This tool demonstrates the data in three sections: Total CVD mortality rates by region Mortality rates by CV disease state Risk factors, location metrics & socioeconomic data Explore each of these interactive settings to delve into these important global data. Published by the Global Burden of CVD Collaboration—an alliance between JACC, the Institute for Health Metrics and Evaluation, and the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2022 Dec, 80 (25) 2372–2425.

    Tweet Tweets with this article
    • Dr. Gregory Roth (@IHME) highlights the Global Burden of #CVD interactive resource on @JACCJournals at #ESCCongress. 🌎 Explore data rich visualization from across 21 regions here: https://t.co/OQTdPyZ9ac #GBDStudy #JACC #CardioTwitter https://t.co/3nHCI1MqAe

    • .#ESCCongress2023: Live now. Insightful JACC Joint session. Location: Hub Mondrian. #Global burden of #CVD & risks: what should #European cardiovascular clinicians do? Also check out the #GBDStudy interactive tool: #JACC #NHLBI #IHME. https://t.co/b8iSqaRBPY #ESCCongress #cvPrev https://t.co/f0maHOsS2P

  • Mashup Score: 0

    August 8, 2023 — Although at greater risk, a new study found that patients of African ancestry with dilated cardiomyopathy (DCM) were less likely to have clinically actionable variants in DCM genes than those of European ancestry. LSU Health New Orleans is one of the 25 clinical sites nationally that enrolled participants in the study. Professor and Chief of Cardiology Dr. Frank Smart leads the LSU Health New Orleans site. The research, which adds critical genetic information about this understudied population, is published in the Journal of the American Medical Association, available here.  “Black patients with cardiomyopathy have an increased familial risk, as well as an increased risk of adverse outcomes from cardiomyopathy compared to white patients,” notes Dr. Smart. “Despite knowing the increased risk in black patients, most patients who have been involved in clinical trials for heart failure have been white. Genetic trials associated with heart failure have had an even more sign

    Tweet Tweets with this article
    • @DAICeditor @lsu Although at greater risk, a new study found that patients of #African ancestry with dilated #cardiomyopathy (#DCM) were less likely to have clinically actionable variants in DCM genes than those of #European ancestry: https://t.co/xTHyPEIgMU

  • Mashup Score: 1

    This study involving 2 large, community-based, longitudinal, cohort studies whether adding 2 markers—coronary artery calcium score and polygenic risk score—to traditional risk factor–based scores improves predicting coronary heart disease among middle-aged to older adults.

    Tweet Tweets with this article
    • .@NIH_NHLBI-funded: In 2 population-based studies involving 3208 adults aged 45-79 years and of #European ancestry, the coronary artery #calcium score but not the #polygenic risk score improved #coronary #HeartDisease risk discrimination. @HeartDocSadiya https://t.co/ZZLtI8p82u https://t.co/Ah6fQ5s6uH

  • Mashup Score: 0

    The European interventional cardiology device market is one of the larger markets in the global space. The market is driven by the regions aging population and the health care systems demands for various medical devices. However, like the rest of the globe, Europe is seeing a rapidly aging population who are requiring more cardiac care in addition to a decline in overall cardiovascular health….

    Tweet Tweets with this article
    • @DAICeditor @iDataResearch The #European #interventional #cardiology market has reached maturity and is now seeing price #depreciation leading to market value declines across most of the market segments: https://t.co/GvOfHO4krW